Acelyrin, Inc. Announces $300 Million Series C Financing To Accelerate Phase 3 Development Of Izokibep, A Unique Il-17A Inhibitor To Treat Inflammatory Diseases
Acelyrin, Inc. Announces $300 Million Series C Financing To Accelerate Phase 3 Development Of Izokibep, A Unique Il-17A Inhibitor To Treat Inflammatory Diseases
09/13/22, 11:04 AM
Location
los angelesMoney raised
$300 million
Round Type
series c
ACELYRIN, INC., a late-stage clinical biopharma company focused on accelerating the delivery of transformative medicines in immunology, today announced a $300 million Series C financing to fund izokibep Phase 3 development in psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA) through anticipated submission of biologic license applications (BLA). Combined with significant cash on hand, the company also will continue development of izokibep in hidradenitis suppurativa (HS) and uveitis, explore several potential new indications, and continue to aggressively pursue portfolio expansion through high-value business development opportunities.
Company Info
Location
los angeles, california, united states
Additional Info
ACELYRIN, INC. (Nasdaq: SLRN) is a Los Angeles area-based late-stage clinical biopharma company – with additional operations in the San Francisco Bay area – focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising product candidates.
ACELYRIN is embedding a corporate culture of Courageous Caring™ -- placing patients first and embracing the concept that all of us are better than any one of us -- as we seek to addresses the most basic human needs: to live a productive life free from diseases.